BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
수요일, 9월 30

Nautilus Biotechnology Inc

NAUTNASDAQ
Trade with Public
Trade with Public
$1.43
0.064.4%
마지막 업데이트: Sep 30, 3:37 PM
PRO
변동 이유?:Nautilus Biotechnology shares are trading higher after Roth Capital initiat...
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Nautilus Biotechnology Analyst Price Targets

Wall Street analyst price targets and consensus rating for Nautilus Biotechnology (NAUT).

Price Target Range — 4 Quarters

Analyst Consensus — 5 Analysts

3Buy
1Hold
1Sell
Consensus RatingBuy# Analysts5Avg. Consensus PT$3Upside to Avg. PT+128.1%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →
DateFirmAnalystActionRating ChangePrice Target
Sep 29, 2026Roth CapitalMax MasucciInitiateBuy$4
Sep 9, 2026Leerink PartnersPuneet SoudaInitiateOutperform$4
More with Benzinga EdgeGet Access

Analyst Ratings News

This SpaceX Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Analysts initiate coverage: Buy on Nautilus ($3.50) and SpaceX ($200); Outperform on FuelCell ($24) and Butterfly ($15); Market Perform on O’Reilly ($94).
Avi Kapoor

PRO
Roth Capital Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $3.5

Roth Capital analyst Max Masucci initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Buy rating and announces Price Target of $3.5.
Benzinga Newsdesk

PRO
Leerink Partners Initiates Coverage On Nautilus Biotechnology with Outperform Rating, Announces Price Target of $4

Leerink Partners analyst Puneet Souda initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Outperform rating and announces Price Target of $4.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Nautilus Biotechnology, Raises Price Target to $4

Guggenheim analyst Subbu Nambi maintains Nautilus Biotechnology (NASDAQ:NAUT) with a Buy and raises the price target from $2.5 to $4.
Benzinga Newsdesk

PRO
Goldman Sachs Downgrades Nautilus Biotechnology to Sell, Lowers Price Target to $1.75

Goldman Sachs analyst Matthew Sykes downgrades Nautilus Biotechnology (NASDAQ:NAUT) from Neutral to Sell and lowers the price target from $2.25 to $1.75.
Benzinga Newsdesk

PRO
Guggenheim Initiates Coverage On Nautilus Biotechnology with Buy Rating, Announces Price Target of $6

Guggenheim analyst Subbu Nambi initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Buy rating and announces Price Target of $6.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved